Molecular Profile | KRAS act mut |
Therapy | Venetoclax + VX-11e |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KRAS act mut | colorectal cancer | no benefit | Venetoclax + VX-11e | Preclinical - Cell culture | Actionable | In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663). | 27974663 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(27974663) | PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. | Full reference... |